Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease

Wang, Xuemei; Yu, Shun; Li, Fangfei; Feng, Tao

doi:10.1016/j.neulet.2015.05.030

Cited by 121 publications

(126 citation statements)

References 27 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…Subsequent studies found oligomeric‐α‐syn to be increased in plasma (Duran et al ), and red blood cells (Papagiannakis et al ), whereas other studies reported no significant differences (Park et al ; Yanamandra et al . ; Wang et al ). In a similar study, Foulds used various ELISA assays to measure concentrations of t‐ and o‐, or pS129‐α‐syn in blood plasma of PD patients compared to healthy controls (Foulds et al .…”

Section: Levels Of α‐Syn In the Blood As A Biomarker For Pdmentioning

confidence: 98%

Parkinson’s disease biomarkers based on α‐synuclein

Fayyad

Salim

Majbour

et al. 2019

Journal of Neurochemistry

112

101

View full text Add to dashboard Cite

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease and is estimated to affect approximately 1–4% of individuals aged over 60 years old. Although considerable efforts have been invested into developing disease‐modifying therapies for Parkinson’s disease, such efforts have been confounded by the difficulty in accurately diagnosing Parkinson’s disease during life to enable accurate patient stratification for clinical trialling of candidate therapeutics. Therefore, the search for effective biomarkers that can be accurately evaluated during life with non‐invasive means is a pressing issue in the field. Since the discovery of α‐synuclein (α‐syn) as a protein linked to a familial form of Parkinson’s disease, later identified as the major protein component of the neuropathological hallmark of idiopathic Parkinson’s disease, considerable interest has focused on this protein and its distinct conformers. We describe here the progress that has been made in the area of Parkinson’s disease biomarker discovery with a focus on α‐synuclein. In particular, we highlight the novel assays that have been employed and the increasing complexity in evaluating α‐synuclein with regard to the considerable diversity of conformers that exist in the biofluids and peripheral tissues under disease conditions. “This article is part of the Special Issue Synuclein.”

show abstract

Section: Levels Of α‐Syn In the Blood As A Biomarker For Pdmentioning

confidence: 98%

Parkinson’s disease biomarkers based on α‐synuclein

Fayyad

Salim

Majbour

et al. 2019

Journal of Neurochemistry

112

101

View full text Add to dashboard Cite

show abstract

“…However, ELISA‐based methods typically can only yield information on the amount of the antigen present in solution. It is possible to indirectly probe the oligomerization of proteins using oligomerization‐specific antibodies with ELISA (X. Wang, Yu, Li, & Feng, ), but quantitative stoichiometry information is highly challenging to extract.…”

Section: Protein Analysis Using Pull‐down Assaysmentioning

confidence: 99%

Recent advancement of light‐based single‐molecule approaches for studying biomolecules

Croop

Zhang

Lim

et al. 2019

WIREs Mechanisms of Disease

View full text Add to dashboard Cite

Recent advances in single‐molecule techniques have led to new discoveries in analytical chemistry, biophysics, and medicine. Understanding the structure and behavior of single biomolecules provides a wealth of information compared to studying large ensembles. However, developing single‐molecule techniques is challenging and requires advances in optics, engineering, biology, and chemistry. In this paper, we will review the state of the art in single‐molecule applications with a focus over the last few years of development. The advancements covered will mainly include light‐based in vitro methods, and we will discuss the fundamentals of each with a focus on the platforms themselves. We will also summarize their limitations and current and future applications to the wider biological and chemical fields. This article is categorized under: Laboratory Methods and Technologies > Imaging Laboratory Methods and Technologies > Macromolecular Interactions, Methods Analytical and Computational Methods > Analytical Methods

show abstract

“…Recent studies indicate that α -synuclein oligomers are increased in red blood cells and CSF of PD subjects and could serve as biomarkers of disease [81, 82]. The levels of α -synuclein are also increased in peripheral lymphocytes [83] as well as in plasma and CNS-derived exosomes of affected individuals [84].…”

Section: Central and Peripheral Localization Of Neuronal α-Synuclementioning

confidence: 99%

The Contribution ofα-Synuclein Spreading to Parkinson’s Disease Synaptopathy

et al. 2017

View full text Add to dashboard Cite

Synaptopathies are diseases with synapse defects as shared pathogenic features, encompassing neurodegenerative disorders such as Parkinson's disease (PD). In sporadic PD, the most common age-related neurodegenerative movement disorder, nigrostriatal dopaminergic deficits are responsible for the onset of motor symptoms that have been related to α-synuclein deposition at synaptic sites. Indeed, α-synuclein accumulation can impair synaptic dopamine release and induces the death of nigrostriatal neurons. While in physiological conditions the protein can interact with and modulate synaptic vesicle proteins and membranes, numerous experimental evidences have confirmed that its pathological aggregation can compromise correct neuronal functioning. In addition, recent findings indicate that α-synuclein pathology spreads into the brain and can affect the peripheral autonomic and somatic nervous system. Indeed, monomeric, oligomeric, and fibrillary α-synuclein can move from cell to cell and can trigger the aggregation of the endogenous protein in recipient neurons. This novel “prion-like” behavior could further contribute to synaptic failure in PD and other synucleinopathies. This review describes the major findings supporting the occurrence of α-synuclein pathology propagation in PD and discusses how this phenomenon could induce or contribute to synaptic injury and degeneration.

show abstract

Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease

Cited by 121 publications

References 27 publications

Parkinson’s disease biomarkers based on α‐synuclein

Parkinson’s disease biomarkers based on α‐synuclein

Recent advancement of light‐based single‐molecule approaches for studying biomolecules

The Contribution ofα-Synuclein Spreading to Parkinson’s Disease Synaptopathy

Contact Info

Product

Resources

About